DNA RNA and Cells

17 Sep 2018 Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care
14 Sep 2018 Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study
13 Sep 2018 Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
12 Sep 2018 Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
10 Sep 2018 Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
08 Sep 2018 CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit
06 Sep 2018 Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate Combination Therapy with CMP-001 and Avelumab
06 Sep 2018 Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer using ET140202 T-cell Therapy
05 Sep 2018 Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
05 Sep 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
05 Sep 2018 Lysogene Announces FDA approval of IND Application to Initiate Phase 2-3 Clinical Trial in MPS IIIA
05 Sep 2018 ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
04 Sep 2018 Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)
04 Sep 2018 SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
31 Aug 2018 Exonics Announces Publication of Research Demonstrating Gene Repair Technology Restored Dystrophin Expression in Canine Model of Duchenne Muscular Dystrophy
30 Aug 2018 Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD
30 Aug 2018 Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe
30 Aug 2018 REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
30 Aug 2018 Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration
28 Aug 2018 Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA
27 Aug 2018 Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
27 Aug 2018 Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
26 Aug 2018 uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
24 Aug 2018 Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
22 Aug 2018 Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up